RWS Unifies Clinical Trial Services to Cut Global Study Timelines
Clinical trials often stall due to fragmented vendor management, where licensing, translation, and migration tasks create compounding delays. RWS is attempting to solve this bottleneck by consolidating eCOA translation and linguistic validation into a single, integrated program team designed to accelerate site activation and regulatory submission timelines.
The new service model replaces disconnected workstreams with a centralized leadership structure. By bringing COA licensing, source validation, multilingual translation, Trados-enabled migration, and rater training under one roof, RWS aims to eliminate the handoffs that frequently blur accountability in global studies. The approach leverages AI-powered automation to handle repetitive tasks, allowing domain experts to focus on maintaining scientific rigor and compliance standards.
Martial Marcotti, EVP and Chief Product Officer at Kayentis, noted that an integrated approach simplifies execution and helps sponsors maintain endpoint quality without the friction of managing multiple vendors. Dan Herron, Global Vice President of Digital Health at RWS, emphasized that clinical teams should not have to compromise on speed to meet regulatory requirements. The company’s expanded digital health portfolio now covers the entire COA lifecycle, from initial instrument acquisition to final global deployment, ensuring consistent governance across all stages of a study.
Comments (0)
No comments yet. Be the first!